EXS 21546
Alternative Names: EVOEXS-21546; EXS-21546Latest Information Update: 21 Nov 2023
At a glance
- Originator Evotec SE; Exscientia
- Developer Evotec - Exscientia (JV)
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 03 Oct 2023 Discontinued - Phase-I for Solid tumours (In volunteers) in United Kingdom (PO)
- 03 Oct 2023 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Second-line therapy or greater) in Europe (PO)
- 06 Dec 2022 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater) in Europe (PO) as of December 2022